Key result
Novel oral anticoagulants and non-pharmacological devices offer cost-effective alternatives to warfarin for stroke prevention in atrial fibrillation, with incremental cost-effectiveness ratios generally below $50,000 per QALY.
Why the study?
Are novel oral anticoagulants and non-pharmacological devices cost-effective compared to warfarin for stroke prevention in patients with atrial fibrillation?
Are novel oral anticoagulants and non-pharmacological devices cost-effective compared to warfarin for stroke prevention in patients with atrial fibrillation?
Novel oral anticoagulants and non-pharmacological devices appear to be cost-effective alternatives to warfarin for stroke prevention in atrial fibrillation across various healthcare systems.
Answers are grounded in this paper and cite their sources.
May support preferring NOACs and devices over warfarin in AF; extends economic reviews but leaves open need for updated real-world models.
Ischaemic/embolic complications are the most common severe consequences of atrial fibrillation. Although chronic anticoagulation with warfarin has been available for decades, it was consistently shown to be underutilised; multiple drug interactions and dietary issues further complicate its use. Recently, several pharmacological and non-pharmacological alternatives have been shown to have an efficacy that is similar or slightly superior to warfarin. Novel anticoagulant agents (dabigatran, rivaroxaban, apixaban) have the advantage of a fixed dose, without the need of regular monitoring. Non-pharmacological options include left atrial appendage ligation or percutaneous closure. Although all these options are more expensive than warfarin, they have the potential of being more cost-effective – preventing very expensive complications or having less side-effects (such as haemorrhagic stroke), requiring less or no monitoring, and having fewer interactions with diet, thus, improving quality of life. Multiple studies of simulated cost-efficacy analyses have been published recently, addressing these questions, which will be reviewed in this paper. In the era of cost-conscious utilisation of healthcare resources, these new treatment options may increase the number of patients benefitting from effective therapies, reducing the number of ischaemic complications of atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Merkely et al. (2013) conducted a review in Atrial fibrillation. Novel oral anticoagulants and non-pharmacological devices vs. Warfarin was evaluated on Cost-effectiveness (Incremental cost-effectiveness ratio). Novel oral anticoagulants and non-pharmacological devices offer cost-effective alternatives to warfarin for stroke prevention in atrial fibrillation, with incremental cost-effectiveness ratios generally below $50,000 per QALY.
Synapse has enriched 10 related papers. Consider them for comparative context: